Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT03129061 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
DRUG: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.

Sponsor

CellSight Technologies, Inc.

Collaborators

[object Object]